Oxygenta [OXYGENTAPH] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Oxygenta Pharmaceutical Ltd.

BSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Oxygenta Pharmaceutical Ltd. wins in 3 metrics, Divi's Laboratories Ltd. wins in 15 metrics, with 0 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Oxygenta Pharmaceutical Ltd. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) 444.32 67.11 Divi's Laboratories Ltd.
Price-to-Book Ratio -5.50 10.82 Divi's Laboratories Ltd.
Debt-to-Equity Ratio -1.99 0.58 Divi's Laboratories Ltd.
PEG Ratio 19.02 4.63 Divi's Laboratories Ltd.
EV/EBITDA -15.15 48.63 Divi's Laboratories Ltd.
Profit Margin (TTM) -15.47% 24.04% Divi's Laboratories Ltd.
Operating Margin (TTM) -14.55% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) N/A 29.65% N/A
Return on Equity 38.69% 14.64% Oxygenta Pharmaceutical Ltd.
Return on Assets (TTM) -11.61% 12.94% Divi's Laboratories Ltd.
Free Cash Flow (TTM) $-87.89M $2.15B Divi's Laboratories Ltd.
Dividend Yield N/A 0.91% N/A
1-Year Return -45.31% 0.83% Divi's Laboratories Ltd.
Price-to-Sales Ratio (TTM) 1.87 16.18 Oxygenta Pharmaceutical Ltd.
Enterprise Value $2.82B $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 2.50 15.86 Oxygenta Pharmaceutical Ltd.
Gross Profit Margin (TTM) -4.06% 63.71% Divi's Laboratories Ltd.
Revenue per Share (TTM) $31 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $-4.72 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) 0.52 0.19 Divi's Laboratories Ltd.

Oxygenta Pharmaceutical Ltd. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

OXYGENTAPH
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Oxygenta Pharmaceutical Ltd.1.71%-5.41%-12.37%-0.30%-20.06%-7.05%
Divi's Laboratories Ltd.0.30%-3.25%-0.65%4.12%1.88%3.66%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Oxygenta Pharmaceutical Ltd.-45.31%60.31%375.14%380.79%624.83%225.39%
Divi's Laboratories Ltd.0.83%89.86%56.44%484.44%1,625.50%9,907.51%

Performance & Financial Health Analysis: Oxygenta Pharmaceutical Ltd. vs Divi's Laboratories Ltd.

MetricOXYGENTAPHDIVISLAB
Market Information
Market Cap i₹2.00B₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i5,432253,443
90 Day Avg. Volume i7,995283,911
Last Close₹50.70₹6,596.50
52 Week Range₹45.30 - ₹133.50₹5,636.50 - ₹7,071.50
% from 52W High-62.02%-6.72%
All-Time High₹133.50 (Jun 09, 2025)₹7,071.50 (Jul 08, 2025)
% from All-Time High-62.02%-6.72%
Growth Metrics
Quarterly Revenue Growth0.02%0.12%
Quarterly Earnings GrowthN/A-0.01%
Financial Health
Profit Margin (TTM) i-0.15%0.24%
Operating Margin (TTM) i-0.15%0.30%
Return on Equity (TTM) i0.39%0.15%
Debt to Equity (MRQ) i-1.990.58
Cash & Liquidity
Book Value per Share (MRQ)₹-9.89₹580.95
Cash per Share (MRQ)₹0.34₹122.95
Operating Cash Flow (TTM) i₹-61,057,000₹19.67B
Levered Free Cash Flow (TTM) i₹-96,826,000₹21.91B
Dividends
Last 12-Month Dividend Yield iN/A0.91%
Last 12-Month Dividend iN/A₹60.00

Valuation & Enterprise Metrics Analysis: Oxygenta Pharmaceutical Ltd. vs Divi's Laboratories Ltd.

MetricOXYGENTAPH (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i444.3267.11
Forward P/E iN/A53.75
PEG Ratio i19.024.63
Price to Sales (TTM) i1.8716.18
Price to Book (MRQ) i-5.5010.82
Market Capitalization
Market Capitalization i₹2.00B₹1.69T
Enterprise Value i₹2.82B₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i2.5015.86
Enterprise to EBITDA i-15.1548.63
Risk & Other Metrics
Beta i0.520.19
Book Value per Share (MRQ) i₹-9.89₹580.95

Financial Statements Comparison: Oxygenta Pharmaceutical Ltd. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricOXYGENTAPH (2025)DIVISLAB (2025)
Revenue/Sales i1.09B93.25B
Cost of Goods Sold i1.08B38.70B
COGS % of Revenue i98.5%41.5%
Gross Profit i16.68M54.55B
Gross Margin i1.5%58.5%
Research & Development iN/A270.00M
Operating Income (EBIT) i-103.50M25.71B
Operating Margin i-9.5%27.6%
EBITDA i-84.49M33.19B
EBITDA Margin i-7.7%35.6%
Pre-Tax Income i-115.53M29.16B
Pre-Tax Income % of Revenue i-10.6%31.3%
Income Tax i-18.70M7.25B
Income Tax % of Revenue i-1.7%7.8%
Net Income (Profit) i-96.83M21.91B
Profit Margin i-8.9%23.5%

Balance Sheet & Liquidity Metrics

MetricOXYGENTAPH (2025)DIVISLAB (2025)
Cash & Equivalents i17,0004.15B
Total Current Assets i309.43M100.81B
Total Current Assets % of Revenue i28.3%108.1%
Total Current Liabilities i858.47M14.52B
Total Current Liabilities % of Revenue i78.5%15.6%
Long-Term Debt i215.22M20.00M
Long-Term Debt % of Revenue i19.7%0.0%
Total Shareholders Equity i-250.25M149.69B
Retained Earnings i-735.63M134.00B
Retained Earnings % of Revenue i-67.3%143.7%
Property, Plant & Equipment i14.36M3.19B

Cash Flow Statement Comparison

MetricOXYGENTAPH (2025)DIVISLAB (2025)
Operating Cash Flow i-61.06M19.67B
Operating Cash Flow % of Revenue i-5.6%21.1%
Capital Expenditures i-112.72M-14.38B
Free Cash Flow i-87.89M2.15B
FCF Margin i-8.0%2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricOXYGENTAPHDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i36.98M265.47M
Float Shares i4.87M117.72M
% Held by Insiders i81.94%52.04%
% Held by Institutions i0.00%28.65%
% Held by Public i18.06%19.31%

Dividend Analysis & Yield Comparison: Oxygenta Pharmaceutical Ltd. vs Divi's Laboratories Ltd.

MetricOXYGENTAPHDIVISLAB
Last 12-Month Dividend iN/A₹60.00
Last 12-Month Dividend Yield iN/A0.91%
3-Year Avg Annual Dividend iN/A₹50.00
3-Year Avg Dividend Yield iN/A0.70%
3-Year Total Dividends iN/A₹150.00
Ex-Dividend DateN/AJul 25, 2025